Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study

BACKGROUND: Neutralizing antibodies (NAbs) against Interferon beta (IFNβ) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNβ treatment. METHODS: We studied the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Sbardella, Emilia, Tomassini, Valentina, Gasperini, Claudio, Bellomi, Francesca, Cefaro, Luca Ausili, Morra, Vincenzo Brescia, Antonelli, Guido, Pozzilli, Carlo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770509/
https://www.ncbi.nlm.nih.gov/pubmed/19825153
http://dx.doi.org/10.1186/1471-2377-9-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770509/
https://www.ncbi.nlm.nih.gov/pubmed/19825153
http://dx.doi.org/10.1186/1471-2377-9-54

Ejemplares similares